Clinical Trials Logo
  1. Home
  2. Lymphoma, Large-Cell, Diffuse
  3. NCT00169130

ACVBP Followed by ASCT in Patients With BCL-2 Positive Diffuse Large B-Cell Lymphoma

Lymphoma, Large-Cell, Diffuse Clinical Trial

Official title:
Prospective Study of ACVBP Followed by Autologous Stem Cell Transplantation in Case of BCL-2 Overexpression in Non Previously Treated Patients Aged 60 Years or Less With Low-Intermediate Risk Diffuse Large B-Cell Lymphoma

Clinical Trial Summary

The primary objective of the study is to evaluate the efficacy of ASCT as consolidation in case of bcl-2 overexpression in non previously treated patients aged 60 years or less with low-intermediate risk diffuse large B-cell lymphoma who responded to ACVBP regimen. Our goal is to obtain a 15% increase of event-free survival at 2 years.

Clinical Trial Description

n/a

Study Design

Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT00169130
Study type Interventional
Source Lymphoma Study Association
Contact
Status Completed
Phase Phase 2/Phase 3
Start date October 1999
View Details
See also
  Status Clinical Trial Phase
Completed NCT00379574 - Bortezomib Plus CHOP Every 2 Weeks for Advanced Stage DLBCL Phase 1/Phase 2
Terminated NCT00514722 - Pilot Study of Umbilical Cord Blood Transplantation in Adult Patient With Advanced Hematopoietic Malignancies N/A
Terminated NCT00135499 - R-ACVBP Versus R-CHOP in Patients Aged 60-65 With Diffuse Large B-cell Lymphoma Phase 3
Terminated NCT00511043 - PTK787 in Refractory or Relapsed Diffuse Large Cell Lymphoma Phase 2
Completed NCT00823719 - Phase II Study of Ofatumumab Plus Ifosfamide, Carboplatin, Etoposide (ICE) or Dexamethasone, Cytarabine, Cisplatin (DHAP) Chemotherapy Regimen in Relapsed/ Refractory Diffuse Large B Cell Lymphoma (DLBCL) Phase 2
Completed NCT01014208 - Ofatumumab Versus Rituximab Salvage Chemoimmunotherapy Followed by Autologous Stem Cell Transplant in Relapsed or Refractory Diffuse Large B Cell Lymphoma Phase 3
Completed NCT00001237 - Pilot Protocol for the Treatment of Patients With Small Non-Cleaved and Diffuse Large Cell Lymphomas Phase 2
Terminated NCT00498914 - Study of YM155 in Refractory Diffuse Large B-cell Lymphoma (DLBCL) Subjects Phase 2
Completed NCT00137995 - R-ICE Versus R-DHAP in Patients Aged 18-65 With Relapse Diffuse Large B-cell Lymphoma Phase 3
Completed NCT00498043 - A Study of Two Associations of Rituximab and Chemotherapy, With a PET-driven Strategy, in Lymphoma Phase 2
Completed NCT00622388 - Ofatumumab in Patients With Relapsed/Progressive Diffused Large B-Cell Lymphoma (DLBCL) Ineligible for or Relapse/Progression After Transplant Phase 2
Completed NCT00561379 - Diffuse Large B Cell Lymphoma of the Adult: Randomization Between High Dose Chemotherapy With Rituximab and CHOP 14-Rituximab N/A